摘要
目的:探讨补肺逐瘀汤治疗慢性阻塞性肺疾病(chronic obstructive pulmo-nary disease,COPD)稳定期的临床疗效。方法:选取2017年1月至2018年10月上海市浦东新区中医医院收治的COPD稳定期患者80例,采用简单随机数字表法分为观察组和对照组,每组40例。两组患者均给予相同的常规西药治疗,观察组患者在此基础上加用补肺逐瘀汤治疗,均治疗2个月。观察两组患者的临床疗效,治疗前后临床症状评分、肺功能指标[第1秒用力呼气容积(FEV1)占预计值百分比(FEV1%)、FEV1与用力肺活量(FVC)比值(FEV1/FVC)及最大呼气流量占预计值百分比(PEF%)]水平、血气分析指标[动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)及动脉血氧饱和度(SaO2)]水平、血清炎症因子[肿瘤坏死因子α(TNF-α)、白细胞介素8(IL-8)]水平及不良反应发生情况。结果:观察组患者的总有效率为92.50%(37/40),明显高于对照组的75.00%(30/40),差异有统计学意义(P<0.05)。治疗后,两组患者临床症状(咳嗽、咯痰、喘息、呼吸困难、紫绀及哮鸣音)评分明显低于治疗前,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05);两组患者FEV1%、FEV1/FVC及PEF%水平均明显高于治疗前,且观察组患者明显高于对照组,差异均有统计学意义(P<0.05);两组患者PaO2、Sa O2水平均明显高于治疗前,PaCO2水平明显低于治疗前,且观察组患者明显优于对照组,差异均有统计学意义(P<0.05);两组患者血清TNF-α、IL-8水平均明显低于治疗前,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05)。两组患者的不良反应均少且轻微。结论:在常规西药治疗基础上联合补肺逐瘀汤治疗COPD稳定期的疗效显著,能有效促进患者临床症状及体征的缓解,改善肺功能和动脉血气状态,抑制机体炎症反应。
OBJECTIVE:To probe into the clinical efficacy of Bufeizhuyu decoction in treatment of chronic obstructive pulmonary disease(COPD)in stable stage.METHODS:80 patients with COPD in stable stage admitted into Pudong Hospital of Traditional Chinese Medicine from Jan.2017 to Oct.2018 were selected and divided into observation group and control group via random number table,with 40 cases in each group.Both groups were given conventional therapy of western medicine,in addition,the observation group was treated with Bufeizhuyu decoction,both groups were treated for 2 months.The clinical efficacy,symptom scores,indices of pulmonary function[the percentage of forced expiratory volume in 1 s(FEV1)accounted for expected value(FEV1%),FEV1/forced vital capacity(FVC),the percentage of peak expiratory flow accounted for expected value(PEF%)]and blood gas analysis[arterial partial pressure of oxygen(PaO2),arterial partial pressure of carbon dioxide(PaCO2)and arterial oxygen saturation(SaO2)],serum inflammatory factors[tumor necrosis factor-α(TNF-α)and interleukin-8(IL-8)]and incidences of adverse drug reactions of two groups before and after treatment were observed.RESULTS:The total effective rate of observation group was 92.50%(37/40),which was significantly higher than that of the control group(75.00%,30/40),with statistically significant difference(P<0.05).After treatment,the symptom scores(cough,expectoration,gasp,dyspnea,cyanosis and wheezing)of both groups were significantly lower than those of before treatment,and those of the observation group were significantly lower than the control group,with statistically significant differences(P<0.05);the FEV1%,FEV1/FVC and PEF%of both groups were significantly higher than those of before treatment,and those of the observation group were significantly higher than the control group,with statistically significant differences(P<0.05);the PaO2 and SaO2 levels of both groups were significantly higher than those of before treatment,while the PaCO2 level was significantly lower,the PaO2,P
作者
金琦
鲍玉芳
李晓英
吴艳芬
JIN Qi;BAO Yufang;LI Xiaoying;WU Yanfen(Dept.of Respiratory,Shanghai Pudong New Area Hospital of Traditional Chinese Medicine,Shanghai 201299,China;Dept.of Nephrology,Shanghai Pudong New Aera People’s Hospital,Shanghai 201299,China)
出处
《中国医院用药评价与分析》
2020年第2期161-165,共5页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
上海市卫生和计划生育委员会科研基金资助项目(No.201640393)
上海市浦东新区卫生系统特色专病资助项目(No.PWZzb2017-30)
上海市浦东新区卫生局基金资助项目(No.PWZq2009-04).
关键词
补肺逐瘀汤
慢性阻塞性肺疾病稳定期
肺功能
血气分析
炎症反应
Bufeizhuyu decoction
COPD in stable stage
Pulmonary function
Blood gas analysis
Inflammatory reaction
